Techniclone -warum steigt sie - 500 Beiträge pro Seite

[sedska]

Hallo,
warum steigt Techniclone 868886 .Weiß jemand um welche News es sich handelt?
Danke

[peterpxx]

habe ich auch bemerkt aber keine ahnung warum

[image2000]

Abkommen mit Merck! Kurzer Auszug:

TUSTIN, Calif.--(BUSINESS WIRE)--Oct. 23, 2000--Techniclone Corporation (NASDAQ:TCLN - news) today announced that the Company has completed an agreement for a segment of its Tumor Necrosis Therapy (TNT) technology with Merck KGaA of Darmstadt, Germany.

Under the agreement, Techniclone will grant Merck the right to use its proprietary TNT antibodies for producing immunocytokines - novel antibody-cytokine fusion proteins used in the treatment of various diseases. Within Merck, the international team of its affiliate Lexigen, based in Lexington, MA, will develop these novel immunocytokines using Techniclone`s TNT technology. The agreement involves an undisclosed upfront payment and a royalty upon commencement of commercial sales.

The TNT technology is Techniclone`s proprietary therapeutic platform designed to specifically target solid tumors by targeting necrotic (dead and dying cells) regions of solid tumors. All solid tumors develop necrotic areas as they grow. The TNT technology invented by Dr. Alan Epstein, Professor of Pathology at USC, is designed to be a single agent capable of treating a larger variety of tumor types. Techniclone is currently in Phase II clinical trials with its TNT construct Cotara(TM) for brain cancer. Cotara(TM) uses a radioisotope, I-131, as its therapeutic agent. It is also in a Phase I study in Mexico for the treatment of pancreatic, liver and prostate cancer.

``This license agreement will allow us the opportunity to explore some promising new therapeutic constructs based on immunocytokines. I am very excited about working with their scientific team to bring these compounds to commercialization`` stated Dr. Alan Epstein.

[sedska]

@image 2000 -danke
na man kann gespannt sein - bin investiert
sedska

[Siby]

Hallo,

Aktie steigt, trotz grauenhafter Stimmung.

Ich glaub fast, das wird was.

Gruß

[cariocca]

@ all

Techniclone wurde im CNBC-Board aufgestuft von HALTEN auf KAUFEN, siehe Link. Es sieht für nächste Woche, wenn die Nasdaq mitspielt, toll aus.

http://cnbc.stkwtch.com/Secop/TCLN.asp?refer=cnbc


Schönes Wochenende

Cariocca

[wütie]

In den letzten Tagen wieder ordentlich gestiegen.
Hat irgendjemand Neuigkeiten über Peregrine Ph.?

[image2000]

Peregrine Pharmaceuticals, früher bekannt als Techniclone, ist ein Biotechunternehmen, welches sich mit der Forschung, der Entwicklung und der Kommerzialisierung von Krebstherapien beschäftigt. Die Firma entwickelt gemeinsam mit Schering ein direktes Tumormittel zur Behandlung Non-Hodgkins B-cell Lymphoma (NHL). Momentan befindet es sich in Phase II, mit der Hilfe dieser Behandlung sollen hohe Dosen an Strahlung direkt den Kern des Tumors beim Verursachen minimalster Beschädigung des umgebenden Gewebes schädigen und zerstören.
Mit einer Marktkapitalisierung von momentan ungefähr 200 Mio. USD ist das Unternehmen günstig bewertet.
Peregrine Pharmaceuticals wird in der nächsten Zeit an einigen Investoren-Treffen und Konferenzen teilnehmen. Davon erhofft man sich, dass mehr Institutionelle auf das Unternehmen aufmerksam werden. Vielleicht werden ja auch neue Forschungsergebnisse bekanntgegeben; das Tumormittel steht unmittelbar vor Phase III.

[image2000]

[image2000]

Scheinbar interessiert sich niemand so richtig für diese Biotech-Perle. (hier im Biotech-Board)
Peregrine hat sich trotz eines miesen Umfeldes recht gut gehalten die letzten Tage.
Am 13. Februar findet in New York ein Wall Street Analysten Forum mit dem Presidenten und CEO von Peregrine, John Bonfiglio, statt. Ich denke, er wird sein Unternehmen gut präsentieren und die Analysten überzeugen.

http://www.peregrineinc.com/index.asp

[image2000]

Peregrine Pharmaceuticals and SuperGen Inc. Announce Finalization of Licensing Deal for VEGF Vascular Targeting Agents
2/13/01
TUSTIN, CA.- February 13, 2001 - Peregrine Pharmaceuticals (Nasdaq: PPHM) and SuperGen Inc. (Nasdaq: SUPG) announced that they have completed a licensing deal for a part of the Vascular Targeting Agent (VTA) technology, specifically related to Vascular Endothelial Growth Factor (VEGF). The total upfront equity investment and milestone payments will ultimately total $8 million. Peregrine will also receive royalties on the net sales of all drugs commercialized by SuperGen utilizing the VEGF technology.

The VTA technology is a proprietary therapeutic platform designed to specifically target tumor vasculature and subsequently destroy the tumor with various attached therapeutic agents. The VTA technology is being developed under a joint venture between Peregrine Pharmaceuticals and OXiGENE, Inc., named ARCUS Therapeutics, LLC.
"This licensing agreement illustrates our strategy of getting the VTA technology into the hands of partners that have the expertise and the resources to develop this increasingly important vascular targeting area," said Edward Legere, Interim President and CEO. "SuperGen will be examining an area of vascular targeting which has great promise as a potential treatment for solid tumors. VEGF has been shown to play an important role in the growth of tumor blood vessels. There is a great deal of work going on in exploring the role that VEGF interactions play in cancer and in other indications. We are confident SuperGen will successfully explore all of these exciting developments."

Peregrine embarked on an aggressive partnership strategy for the VTA technology last year in an effort to insure the rapid development of the VTA area. The SuperGen agreement, the ARCUS joint venture and the previously announced licensing deal with Scotia Holdings are all the results of this strategy. The licensing deal for the VEGF technology falls outside of the ARCUS joint venture with all milestone and licensing fees belonging to Peregrine although royalties from products developed under this agreement will belong to the joint venture. "Together with the candidates being developed by ARCUS and other licensing deals under discussion between ARCUS and potential partners, we are leveraging this technology and its impressive patent portfolio in a way that should maximize the ability to commercialize VTA products," said Legere.

"Peregrine now has five corporate partners for different cancer therapeutic drugs. Peregrine also plans to begin a Phase III trial for its Tumor Necrosis Therapy drug Cotara™. We believe Peregrine is becoming a key player in the cancer therapeutics industry." Legere concluded. "We have long believed that the VTA technology, especially Vascular Endothelial Growth Factor, may be a unique and targeted method of attacking solid tumors," said Dr. Joseph Rubinfeld, Chairman and Chief Executive Officer of SuperGen. "Now that the transaction is complete, the next step will be to begin preclinical studies utilizing this technology with chemotherapy, radiation and photodynamic therapy." technology with chemotherapy, radiation and photodynamic therapy."

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer, primarily based on its "collateral targeting technologies. These technologies therapeutically target cell structures and cell types, rather than surface cancer cells, as a means to attack solid tumors, without causing damage to surrounding healthy tissue. The Company has three collateral targeting technologies: Cotara™, Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents, (VTA). The Company also has a direct tumor-targeting agent called Oncolym® for the treatment of advanced non-Hodgkin`s B-cell Lymphoma. Oncolym® has been licensed to Schering AG, Germany, which is now responsible for all existing and future Oncolym® clinical trial programs as well as marketing.

[KarlPaul]

http://biz.yahoo.com/prnews/010222/lath005.html

[image2000]

Im Journal "Cancer Research" ist ein sehr positiver Artikel über die von PPHM und OXGN entwickelte Vascular Targeting Agent (VTA) Technologie veröffentlicht worden.

[image2000]

Hier mal eine interessante Übersetzung eines Beitrags bei clear-station.com

Suchen nach der Heilung zum Krebs!

(PPHM) Peregrine Pharmaceuticals, Inc.,
ist eine biopharmazeutische Firma, die an der Forschung, der Entwicklung und der Kommerzialisierung der gerichteten Krebstherapeutik teilnimmt. Die Firma entwickelt die Produktanwärter, die hauptsächlich auf dem kollateralen basieren (indirekten) Tumor, der für die Behandlung der festen Tumoren zielt.

Zusätzlich ist die Firma gemeinsam mit Schering A.G. zum Entwickeln eines direkten Tumor-zielenden Mittels (Oncolym) für die Behandlung des B-Zellenlymphoms Non-Hodgkins (NHL)beteilligt.

http://www.peregrineinc.com

mit neuen Nachrichtenfreigaben ihres Erfolges, der ihr zielendes Gefäßmittel (VTA) validiert, a-Technologie für das Behandeln des Krebses.

Sachen schauen während ihrer Zukunft hell.

Sie sieht auch wie Institutionskunden aus und beginnend, Begriff ihrer Anstalten der rezenten Arbeit

zu nehmen vor kurzem sind die Nettokunden der PPHM-Anteile Anteil 1.650.000 am vorherigen Viertel, eine 28%-Zunahme kaufend vom vorhergehenden Viertel gewesen.

Arcus-Therapeutik, LLC: eine Joint Venture zwischen pharmazeutischen Produkten Peregrine (Nasdaq: PPHM) und OXiGENE, Inc..

Berichtete neue Studienerscheinen Gefäßzielen können Tumoren in den Mäusen verhungern validiert das Vorangehen mit Arbeits-

GESCHÄFTSCLeitung -- Feb. 22, 2001 -- arcustherapeutik, LLC, eine Joint Venture zwischen pharmazeutischen Produkten Peregrine (Nasdaq: PPHM - Nachrichten) und OXiGENE, Inc. (Nasdaq: OXGN; SSE: OXGN), heute verkündet, daß eine Publikation in der Journalkrebsforschung zielende Gefäßtechnologie des Mittels ARCUS`s (VTA) für das Behandeln des Krebses validiert. VTAs sind krebsbekämpfende Mittel, die nach dem Abschneiden des Zubehör des Sauerstoffes verfahren und Nährstoffe zur Gruppe des Tumor

zellen- Dr. Neris drei Arten feste Tumoren in den Mäusen mit der Richtung eines gerinnenden Proteins des Bluts behandelten, abgespalteter Gewebefaktor (tTF), zu einer molekularen Markierung (das ED-bgebiet von fibronectin) natürlich ausgedrückt auf dem Tumorvasculature. Einmal beschränkt zu den Tumor$blutgefässen, aktivierte das Gewebefaktorprotein eine Kettenreaktion, die zu die Anordnung der Blutklumpen führt, die die $blutgefässe blockten, dadurch esverhungert esverhungert den Tumor. An den höchsten Dosen (35 ug des Proteins), beobachtete Dr. Neri komplette Tumorentwurzelung ohne offensichtliche Nebenwirkungen in 30% der behandelten Mäuse.

Dieses ist therapeutisch aus drei Gründen relevant: 1. Der Markierungsdr. verwendeter Neri wird in den Tumorbehältern in beiden Mäusen gefunden und Menschen 2. wird es in einer Majorität konkurrenzfähigen festen Tumoren ausgedrückt, 3., die es nicht in den normalen Behältern und in den Geweben erscheint.

[KarlPaul]

(also, hier verstehe ich deutlich weniger als im Original)

[image2000]

Schlechtes Übersetzungsprogramm!

[image2000]

ARCUS Therapeutics to Receive Royalties From Licensing of Its Vascular Targeting Agent Technology

WATERTOWN, Mass., STOCKHOLM, Sweden and TUSTIN, Calif., Feb. 27 /PRNewswire/ -- ARCUS Therapeutics, LLC, a joint venture between Peregrine Pharmaceuticals (Nasdaq: PPHM) and OXiGENE, Inc. (Nasdaq: OXGN; SSE: OXGN), announced today that pursuant to a licensing deal between Peregrine and SuperGen Inc. (Nasdaq: SUPG) it will receive royalty payments on the net sales of all drugs commercialized by SuperGen using ARCUS`s Vascular Targeting Agent (VTA) technology as it relates to Vascular Endothelial Growth Factor (VEGF).

The VTA technology is a proprietary platform designed to target a tumor`s blood supply and destroy the tumor through the use of attached therapeutic agents. The technology can be used with a variety of effector molecules, including drugs, coagulants, radioisotopes, and toxins. ARCUS plans to aggressively seek out-licensing uses of this VTA technology.

In addition to the SuperGen out-licensing, in August 2000, a segment of the VTA technology was licensed to Scotia Pharmaceuticals Limited specifically relating to applications of its Photodynamic Therapy Agents (PDT). ARCUS will receive royalties if Scotia commercializes a product utilizing this area of the VTA technology.

"We believe these agreements demonstrate the depth and robustness of the VTA platform and exemplify ARCUS`s long-term strategy of out-licensing various segments of the technology which will not be developed by the joint venture," said Edward Legere, Director and Interim President and CEO of Peregrine Pharmaceuticals.

"The VEGF represents one potential application of the VTA Technology, and we look forward to working with SuperGen as they undertake its development," said Bjorn Nordenvall, M.D., Ph.D., Chairman and CEO of OXiGENE, Inc. "ARCUS intends to aggressively seek additional licensing deals in the future."

ARCUS Therapeutics, LLC is a joint venture established in May 2000 between Peregrine Pharmaceuticals (Nasdaq: PPHM) and OXiGENE, Inc. (Nasdaq: OXGN; SSE: OXGN) for the development of Vascular Targeting Agents (VTAs) to treat a wide variety of cancers. Combining Peregrine`s VTA technology and OXiGENE`s next-generation tubulin binding compounds, in conjunction with broad patent coverage, ARCUS is positioned to be a premier vascular targeting company.

[image2000]

Dr. Kenneth Cheng to Speak At South Carolina Society of Nuclear Medicine Conference

Using Cotara to Treat Brain Cancer

TUSTIN, Calif.--(BUSINESS WIRE)--March 2, 2001--Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM - news) announced today that Dr. Kenneth Cheng, Ph.D., BCNP, FAPhA, Associate Professor and Director of the Nuclear Pharmacy Program at the Medical University of South Carolina, will speak at the South Carolina Society of Nuclear Medicine Conference in Charleston, S.C. on March 3, 2001. His presentation is titled ``Therapeutic Applications of Radiopharmaceuticals.``

Dr. Cheng will discuss his clinical experience with Cotara(TM), Peregrine`s Tumor Necrosis Therapy (TNT) drug. Dr. Cheng participated as a researcher in the Phase I and II brain cancer trials for Cotara that were conducted at the Medical University of South Carolina. Cotara is a radiolabeled monoclonal antibody that targets the necrotic core of tumors.

``We are extremely pleased that there is increasing recognition of the potential for radiolabeled monoclonal antibodies such as Cotara in the treatment of cancer,`` said Dr. Terrence Chew, Vice President of Clinical and Regulatory Affairs. ``We are fortunate to be associated with Dr. Cheng who has made significant contributions to the program at the Medical University of South Carolina.``

``We are pleased to have Dr. Cheng share his clinical experiences with his colleagues in the Nuclear Medicine field,`` said Mr. Edward Legere, Director and Interim President and CEO. ``Such exposure will help us as we advance Cotara into a Phase III trial for brain cancer. We encourage all researchers in our clinical programs to give presentations and publish their clinical experiences for peer review, thus increasing exposure for Cotara and our other clinical programs.``

[image2000]

Peregrine Announces Research and Development Agreement With Paul Scherrer Institut for TNT Based PET Imaging Agents

Continues Radiolabeling Research and Development

TUSTIN, Calif.--(BUSINESS WIRE)--March 13, 2001--Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM - news) announced today that it has extended its radiolabeling research and development agreement with Paul Scherrer Institut (PSI), Villigen, Switzerland. Peregrine has extended its contract with PSI to include research, development and pre-clinical testing of Tumor Necrosis Therapy (TNT) based Positron Emission Tomography (PET) Imaging agents. Peregrine has been collaborating with the Paul Scherrer Institut to scale-up the radiolabeling processes for its Cotara(TM) and Oncolym® products.

``We are pleased to continue to work with the Paul Scherrer Institut on our radiolabeling development,`` said Steven King, Vice President of Technology and Product Development. ``PSI has been instrumental in developing methods for large-scale radiolabeling of our Cotara and Oncolym® monoclonal antibody based anti-cancer drugs. We believe that we now have a process in place that should allow us to produce commercial quantities of our radiolabeled therapeutic antibodies. PSI will now focus on standardizing and automating this process to ensure reproducibility and quality across manufactured lots.``

``PSI has extensive experience with our TNT antibodies and PET imaging agents``, stated Steven King. ``We feel PSI will be able to make significant research and development progress toward evaluating a TNT based PET imaging agent this year. We believe there is a large unmet need for advanced PET imaging agents in the market place, and TNT appears to be well suited as a delivery vehicle for PET based imaging agents.``

PET imaging technology is based on cellular metabolism -- the chemical reaction that drives the human body. PET imaging is non-invasive, and researchers have shown the potential advantages of using positron emission tomography (PET) over structural imaging, including conventional X-Ray, magnetic resonance imaging (MRI), and computerized tomography (CT). PET imaging is sensitive enough to detect microscopic tumor cells where as other imaging technology may not recognize these until they were larger. PET cancer imaging is a fast growing market and is becoming a standard test for detecting and managing many cancers.

One of the most important benefits of PET imaging is that it can show physicians whether a particular therapy is effective or not soon after treatment. Early signs of effectiveness can ensure cancer patients are receiving the right cancer treatment. If no efficacy is seen shortly after treatment, the drug can be changed. Detecting drug effectiveness in real time can be a very valuable tool in cancer therapy, ensuring cancer patients are receiving effective therapies.

Peregrine believes TNT is well suited for the delivery PET imaging agents for the real-time measurement of the effectiveness of cancer therapies. Cancer physicians are interested in the amount of cancer cells being killed by a treatment, in essence measuring necrotic cancer tissue. Since TNT targets necrotic cancer tissue, it should be an effective targeting molecule. Peregrine`s researchers have shown that TNT is very effective in finding and attaching to recently killed necrotic tissue. TNT has demonstrated the ability to selectively bind to and accumulate in significant volumes in necrotic cancer tissue. Targeted delivery of PET imaging agents should provide improved images for physicians to work with.